|Babson Diagnostics Inc., of Austin, Texas||Babson Diagnostics aC19G1||Serology test||For the qualitative detection of IgG antibodies to SARS-CoV-2||Received emergency use authorization from the U.S. FDA|
|Circadia Health, of London||C100 system||AI-powered contactless monitoring platform; uses radar to sense wirelessly, from up to 4 feet away in adult patients||Measures respiratory rate||Received 510(k) clearance from the U.S. FDA|
|Ekso Bionics Holdings Inc., of Richmond, Calif.||Eksonr||Robotic exoskeleton||For rehabilitation use in patients with acquired brain injury||Received 510(k) clearance from the U.S. FDA; was previously cleared by the FDA for stroke and spinal cord injury rehabilitation|
|Medtronic plc, of Dublin||Percept PC system||Deep brain stimulation implant; Brainsense technology chronically captures and records brain signals while delivering therapy||Treats patients with neurologic disorders associated with Parkinson's disease, essential tremor, dystonia, epilepsy or obsessive-compulsive disorder||Received U.S. FDA approval|
|Nyxoah SA, of Mont-Saint-Guibert, Belgium||Genio||Battery-free, leadless and minimally invasive implanted neurostimulator||Keeps the upper airway open during sleep for certain people with obstructive sleep apnea by bilateral stimulation of the hypoglossal nerve||Received investigational device exemption approval from the U.S. FDA to commence the pivotal DREAM study|
|Viraxclear, of Vancouver, British Columbia||COVID-19 Rapid Antibody Test Kits||Lateral flow immunoassay||For the qualitative detection of both early and late marker IgG/IgM antibodies to SARS-CoV-2||Received distribution approval from the Philippines Food And Drug Administration|
For more information about individual companies and/or products, see Cortellis.